RankAlpha logo
Back to Rankings

AXSM

Axsome TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
View Chart
Current thesis
The post-earnings bull read is that Axsome is now showing a rare mix for mid-cap biopharma: strong commercial growth, a fresh label expansion for AUVELITY, and management’s statement that current cash should fund operations into cash-flow positivity. The June 2026 Alzheimer’s agitation launch is the key operating lever if investors keep rewarding execution over near-term losses.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
AUVELITY prescriptions were up 35% year over year but were described as consistent with 4Q25, which could imply a flatter near-term volume cadence until the new indication contributes.
Momentum
40
Value
41
Sentiment
44
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $224.00 · Bull $245.00 · Bear $185.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $280.53
Why
Momentum40 · Δ7d -31.3
Value41 · Δ7d +0.0
Sentiment44 · Δ7d -1.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
40
26% active weight
Current posture
7d trendSoftening
Δ7d
-31.3
Δ21d
-55.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
44
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.8
Δ21d
+2.8
Why this grade

Composite grade D. Momentum 40.1 / Value 41.1 / Sentiment 44.1

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$11.41B
Beta
0.40
Shares Out
51.46M
P/E (TTM) · Derived
-60.2
P/S (TTM)
15.40
P/FCF (TTM) · Derived
-156.88
Rev YoY
+57.4%
EPS YoY
+3.7%
Gross Margin
+91.3%
Op Margin
-39.7%
Net Debt
-$104.82M
Current Ratio
1.39
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology